Nuvectis Pharma (NVCT)
US Market

Nuvectis Pharma (NVCT) Stock Price & Analysis


NVCT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$6.21 - $20.92
Previous Close$11.76
Average Volume (3M)61.13K
Market Cap
Enterprise Value$153.42M
Total Cash (Recent Filing)$19.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-8.0
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding14,642,483
10 Day Avg. Volume94,711
30 Day Avg. Volume61,134
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)7.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-14.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.98
Price Target Upside78.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $6.21 and its highest was $20.92 in the past 12 months.
    What is Nuvectis Pharma’s market cap?
    Currently, no data Available
    When is Nuvectis Pharma’s upcoming earnings report date?
    Nuvectis Pharma’s upcoming earnings report date is May 09, 2023 which is in 44 days.
      How were Nuvectis Pharma’s earnings last quarter?
      Nuvectis Pharma released its earnings results on Mar 07, 2023. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.397 by -$0.093.
        Is Nuvectis Pharma overvalued?
        According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Nuvectis Pharma pay dividends?
          Nuvectis Pharma does not currently pay dividends.
          What is Nuvectis Pharma’s EPS estimate?
          Nuvectis Pharma’s EPS estimate is -$0.44.
            How many shares outstanding does Nuvectis Pharma have?
            Nuvectis Pharma has 14,752,403 shares outstanding.
              What happened to Nuvectis Pharma’s price movement after its last earnings report?
              Nuvectis Pharma reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.397. Following the earnings report the stock price went down -4.706%.
                Which hedge fund is a major shareholder of Nuvectis Pharma?
                Currently, no hedge funds are holding shares in NVCT


                Nuvectis Pharma Stock Smart Score

                The Nuvectis Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Nuvectis Pharma

                Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.


                Top 5 ETFs holding NVCT

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold NVCT. The ETFs are listed according to market value of NVCT within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Senti Biosciences
                Candel Therapeutics
                Alzamend Neuro
                Olema Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis